Renal drug transporters and their significance in drug–drug interactions

被引:19
作者
Jia Yin [1 ]
Joanne Wang [1 ]
机构
[1] Department of Pharmaceutics,University of Washington
基金
美国国家卫生研究院;
关键词
Renal drug transporters; Drug–drug interactions; Organic cations; Organic anions; Nephrotoxicity;
D O I
暂无
中图分类号
R969.2 [药物相互作用];
学科分类号
100602 ; 100706 ;
摘要
The kidney is a vital organ for the elimination of therapeutic drugs and their metabolites.Renal drug transporters,which are primarily located in the renal proximal tubules,play an important role in tubular secretion and reabsorption of drug molecules in the kidney.Tubular secretion is characterized by high clearance capacities,broad substrate specificities,and distinct charge selectivity for organic cations and anions.In the past two decades,substantial progress has been made in understanding the roles of transporters in drug disposition,efficacy,toxicity and drug–drug interactions(DDIs).In the kidney,several transporters are involved in renal handling of organic cation(OC) and organic anion(OA) drugs.These transporters are increasingly recognized as the target for clinically significant DDIs.This review focuses on the functional characteristics of major human renal drug transporters and their involvement in clinically significant DDIs.
引用
收藏
页码:363 / 373 +518
页数:12
相关论文
共 40 条
  • [1] Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins
    Yin, Jia
    Duan, Haichuan
    Shirasaka, Yoshiyuki
    Prasad, Bhagwat
    Wang, Joanne
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (12) : 1872 - 1881
  • [2] Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance[J] . J A Sprowl,L Doorn,S Hu,L Gerven,P Bruijn,L Li,A A Gibson,R H Mathijssen,A Sparreboom.Clinical Pharmacology & Therapeutics . 2013 (5)
  • [3] Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium[J] . K M Hillgren,D Keppler,A A Zur,K M Giacomini,B Stieger,C E Cass,L Zhang.Clinical Pharmacology & Therapeutics . 2013 (1)
  • [4] ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans
    Zamek-Gliszczynski, M. J.
    Lee, C. A.
    Poirier, A.
    Bentz, J.
    Chu, X.
    Ellens, H.
    Ishikawa, T.
    Jamei, M.
    Kavass, J. C.
    Nagar, S.
    Pang, K. S.
    Korzekwa, K.
    Swaan, P. W.
    Taub, M. E.
    Zhao, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 64 - 79
  • [5] In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development
    Brouwer, K. L. R.
    Keppler, D.
    Hoffmaster, K. A.
    Bow, D. A. J.
    Cheng, Y.
    Lai, Y.
    Palm, J. E.
    Stieger, B.
    Evers, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 95 - 112
  • [6] The SLC22 family with transporters of organic cations, anions and zwitterions[J] . Hermann Koepsell.Molecular Aspects of Medicine . 2013 (2-3)
  • [7] The SLCO (former SLC21 ) superfamily of transporters[J] . Bruno Hagenbuch,Bruno Stieger.Molecular Aspects of Medicine . 2013 (2-3)
  • [8] Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)
    Li, Qing
    Guo, Dong
    Dong, Zhongqi
    Zhang, Wei
    Zhang, Lei
    Huang, Shiew-Mei
    Polli, James E.
    Shu, Yan
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 273 (01) : 100 - 109
  • [9] Renal Transporters in Drug Development[J] . Kari M. Morrissey,Sophie L. Stocker,Matthias B. Wittwer,Lu Xu,Kathleen M. Giacomini.Annual Review of Pharmacology and Toxicology . 2013
  • [10] Drug transport by Organic Anion Transporters (OATs)
    Burckhardt, Gerhard
    [J]. PHARMACOLOGY & THERAPEUTICS, 2012, 136 (01) : 106 - 130